Why the study?
Due to warfarin's late onset, long-lasting action, and intense food and drug interactions, newer oral anticoagulants have emerged for patients requiring prophylaxis and treatment of thromboembolic events.
This article reviews the management of patients taking traditional and novel oral anticoagulants who require dental procedures.
Answers are grounded in this paper and cite their sources.
May inform periprocedural dental protocols for NOAC users; leaves open need for prospective validation before practice change.
An increasing number of patients in our country use oral anticoagulants for the prophylaxis and treatment of thromboembolic events. The cornerstone of these groups of agents is warfarin, a vitamin K antagonist, which has been the single alternative used by oral route for several years. However, due to warfarin's late onset and long lasting action and the intense interactions with food and drugs, newer oral anticoagulants have emerged in the market in recent years. Dabigatran, rivaroxaban and apixaban are the novel agents used in our country.
No takes yet. Share an insight, caveat, or question.
Doğanay et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: